Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2021-11-22 Earnings Release
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update
Earnings Release Classification · 1% confidence The document is explicitly identified as a 'Form 6-K' filed with the SEC. The text states that the registrant 'issued a press release providing a business update and announcing its financial results for the third quarter of 2021.' The content itself is the press release detailing business highlights, clinical trial updates (Sepsis, COVID-19, Solid tumors), corporate news, and the 'Third Quarter 2021 Financial Results' (key highlights, not the full detailed financial statements typically found in a 10-Q or 10-K). A Form 6-K is used by Foreign Private Issuers to report material information not otherwise required to be reported in their home country or to the SEC. The content strongly aligns with an Earnings Release (ER) or a comprehensive Interim Report (IR), but since the filing itself is the Form 6-K which *contains* the press release announcing the results, and the document focuses heavily on the results announcement and business update, the most fitting category among the provided options for the *content* is the Earnings Release (ER) or Interim Report (IR). Given the document explicitly mentions 'financial results for the third quarter ended September 30, 2021' and provides the key financial figures, it functions as an Earnings Release (ER). If it were a comprehensive quarterly report, it would be IR. Since it is a press release attached to a 6-K announcing the results, ER is the best fit for the primary purpose of the attached exhibit. Q3 2021
2021-11-22 English
Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update
Report Publication Announcement Classification · 1% confidence The document is very short (1767 characters) and explicitly states, "Attached hereto is a report on *6-k* *6K22112021_isa.pdf*". This structure—a brief announcement stating that a formal report (in this case, a Form 6-K, which is an SEC filing for foreign private issuers) is attached or published—fits the definition of a Report Publication Announcement (RPA). It is not the full 6-K report itself, but the notice of its publication. The presence of the Israel Securities Authority and Tel Aviv Stock Exchange context confirms it is a regulatory filing announcement.
2021-11-22 English
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020
Interim / Quarterly Report Classification · 1% confidence The document is a Form 6-K filed with the SEC by Enlivex Therapeutics Ltd. It contains unaudited condensed consolidated financial statements for the three and nine-month periods ended September 30, 2021. Since it provides comprehensive financial data for an interim period (less than a full fiscal year), it is classified as an Interim/Quarterly Report (IR). 9M 2021
2021-11-20 English
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020
Report Publication Announcement Classification · 1% confidence The document explicitly states it is a 'Report of Periodic or Interim Report' filed under Israeli regulations ('Regulation 3 of the Securities Regulations'). It mentions an attached report, specifically referencing a '*6-k* file' (which is an SEC form often used by foreign private issuers, consistent with the text stating 'The corporation is a foreign private issuer'). The document itself is very short (1881 characters) and serves primarily to announce the availability of the actual report ('Attached hereto is a report on *6-k* *6k19112021_isa.pdf*'). According to Rule 2, when a document announces the publication of a report rather than containing the full report, it should be classified as a Report Publication Announcement (RPA). Since this is an announcement of a periodic/interim report, RPA is the most appropriate classification based on the 'Menu vs Meal' rule.
2021-11-20 English
Spanish Regulator Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain
Regulatory Filings Classification · 1% confidence The document explicitly states it is a "Form 6-K" filed with the SEC. Form 6-K is the standard filing for a Foreign Private Issuer to report material information that is made public in its home country or to its shareholders. The content is a press release announcing regulatory clearance for a clinical trial expansion. While it contains financial/operational news, the primary document structure is the SEC filing wrapper (Form 6-K) containing an exhibit (Press Release). Since Form 6-K is not one of the explicitly defined codes (like 10-K, IR, ER), and it serves as a general regulatory disclosure for foreign issuers, the most appropriate fallback category is 'Regulatory Filings' (RNS), as it represents a mandatory, non-standardized SEC submission for this type of issuer reporting material events.
2021-11-10 English
Spanish Regulator Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain
Report Publication Announcement Classification · 1% confidence The document is very short (1767 characters) and explicitly states, "Attached hereto is a report on *6-k* *6k10112021_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a 6-K filing, which is typically an immediate report filed with the SEC by foreign private issuers). According to Rule 2, when a document is short and announces the availability of a report, it should be classified as a Report Publication Announcement (RPA). The presence of the Israel Securities Authority and Tel Aviv Stock Exchange references confirms it is a regulatory filing announcement, but RPA is more specific for this format.
2021-11-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.